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Abstract 
Introduction 
 Venous thromboembolism (VTE) is a common post-operative renal transplant 
complication. VTEs are not only life-threatening, but also require longer hospital stays and/or 
hospital readmission. There are no universally accepted VTE screening guidelines for renal 
transplant recipients (RTRs). The Caprini risk assessment model was the most widely used and 
validated VTE screening tool in the literature. It was adapted and used in this project’s 
intervention. In collaboration with The Queen’s Medical Center Transplant Center (QMCTC), an 
evidence-based quality improvement project was conducted to address the incidence of VTE. 
The Iowa Model was used framework to guide the process. The purpose of this evidenced-based 
practice (EBP) project was to implement and evaluate a program that decreased the incidence of 
venous thromboembolism (VTE) in adult QMCTC patients following renal transplant surgery. 
Methods 
 The target population was the QMCTC RTRs who underwent surgery. Patients were 
screened using the QMCTC-adapted Caprini tool prior to surgery. The results from the 
assessments were then forwarded to the transplant physician team. Methods to assess the 
program outcomes included monitoring VTE incidence during the implementation period and 
physician survey.  
Results 
 During the five-month intervention period, 22 potential candidates for renal transplant 
were screened, while only 12 underwent surgery. Age and history of major surgery were the only 
identified risk factors. Zero incidence of VTE was recorded and the overall VTE incidence rate 
decreased by 0.5%.  
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Discussion 
 The results suggested screening RTRs prior to surgery may decrease the incidence of 
VTE. Although correlational, the results from the project supported the continued use of the 
intervention as a cost-saving measure to enhance patient care. Additional implications included 
raising awareness on VTE and the benefits of EBP projects.  
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CHAPTER 1. EXECUTIVE SUMMARY 
Introduction 
Background/problem. Thromboembolism is a common post-operative renal transplant 
complication. Venous thromboembolisms (VTEs) are life-threatening. They require longer 
hospital stays and/or hospital readmission. Daily costs resulting from VTEs have been estimated 
at $1,664 per patient (Dasta et al., 2014).  
Currently, there are no universally accepted VTE prophylaxis guidelines for renal 
transplant patients. During an investigation into the causes of the VTEs, a survey of The Queen’s 
Medical Center Transplant Center (QMCTC) surgeons revealed varying VTE prophylaxis 
treatment plans based on individual surgeon experience and preference. Some favored only early 
ambulation and intermittent pneumatic compression (IPC), while others opted for pharmacologic 
interventions.  
Studies have indicated this incidence can range from 7.9% to 9.1% (Poli et al., 2006; 
Verhave et al., 2014). Since 2014, Honolulu, Hawai`i’s QMCTC conducted 124 renal transplant 
surgeries. Seven cases of VTE have been reported within six months after surgery—a 5.6% 
incidence. This was the trigger for this evidence-based practice (EBP) project. While the 
incidence rate was below the literature rate, four reported VTEs within a year prompted the need 
for this project.  
Conceptual framework. Implementing change within a large organization required a 
systems-based approach. Titler et al.’s (2001) Iowa Model utilizes an algorithmic flowchart 
approach, which tracks project implementation and employs feedback loops.  
Literature review and synthesis. The search was split up into several subtopics: VTE 
risk factors, VTE risk assessment, and VTE prophylaxis. An electronic search was completed 
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utilizing PubMed, CINAHL, Google Scholar, National Guideline Clearinghouse, and the 
Cochrane Library. 
Eighty-seven articles published between 1997 and 2016 were identified. Forty-four 
articles were omitted based on relevance to this project. The remaining 43 were examined. Four 
clinical practice guidelines (CPGs) were also scrutinized. 
Following the literature synthesis, the Caprini risk assessment model (RAM) appeared to 
be most widely used and validated VTE RAM. Studies evaluating the validity of the scores and 
value for predicting VTE events have received much support (Bilgi et al., 2016; Grant et al., 
2016; Lobastov et al., 2016; Obi et al., 2015; Zhou et al., 2014). Mentions of other VTE RAMs 
were limited and generally cited in comparison with the Caprini RAM.  
Methods 
Design. This project examined the effect of a VTE risk assessment screening program on 
the occurrence of VTE in QMCTC adult renal transplant patients. The evaluation design was 
impact and pre-test/post-test of VTE incidence.  
Practice change description. A modified version of the Caprini RAM was selected and 
adapted to QMCTC’s specifications. Redundant or not applicable risk factors were removed. 
Risk factors identified in the literature were added. The modified VTE risk assessment tool was 
administered to renal transplant patients prior to surgery. The results from the assessment were 
then forwarded to the transplant physician team.  
Setting and sample. This EBP Doctor of Nursing Practice project was conducted at 
QMCTC—the only organ transplant center in Hawai`i and the Pacific Rim (Queen’s Transplant 
Center, 2014b). The transplant center provides five transplant program including liver, adult 
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kidney, pediatric kidney, pancreas, and living kidney transplant programs (Queen’s Transplant 
Center, 2014c).   
The target population was the renal transplant patients undergoing the assessment. The 
sample patient population included all QMCTC RTRs age 18 or older undergoing renal 
transplant surgery during the implementation period. All patients who fit the inclusion criteria 
were included in the sample. 
Data collection. During the screening process prior to surgery, each renal transplant 
patient’s medical record was reviewed for risk factors as indicated by the risk assessment tool. 
Any information not available or unclear from the medical record was asked to the patient 
directly. Each patient was assigned a number and had their own risk assessment file. Identifying 
information was not recorded. A summary of each patient’s VTE risk assessment was forwarded 
to the transplant physician team as they were processed.  
For the incidence of VTE, data was obtained from the medical record or by patient report 
and verification. In the event of a reported VTE, the number of days post-operation to incidence 
was recorded. All information was stored on an encrypted database at QMCTC. Access was only 
available to authorized team members.  
Results 
Description of participants. Twenty-two patients were potential candidates for renal 
transplant during the implementation period. Twenty-one of those patients were above the age of 
18 and met inclusion criteria and underwent VTE risk assessment screening. Twelve of those 
patients underwent renal transplant surgery. Eleven of the patients were male (92%). The 
average age of the patient population was 49 years (range 28 to 68 years), with four patients each 
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in the under 40 years, 40 to 60 years, and above 60 years age groups. Most of the patients were 
Asian or part-Asian (92%), while 17% of the patients were Caucasian or part-Caucasian. 
Data analysis findings. 
Level 1 Risk Factors. The most predominant Level 1 Risk Factors were age 40-59 years 
(33%) and major surgery (25%). 
Level 2 Risk Factors. Age 60 to 74 years was the only Level 2 Risk Factor (33%). 
Level 3 Risk Factors. There were no Level 3 Risk Factors identified in the sample 
population. 
Literature risk factors. For literature risk factors, low hematocrit (less than 40% for 
males and less than 36% for females) was identified in 92% of the patient sample (range 28.8% 
to 39%). 
During the five VTE checks at the end of August, September, October, November, and 
December 2017, zero incidence of VTE was noted in the RTR records. The VTE incidence rate 
in the RTR patient sample was 0%. The overall incidence rate since 2014 decreased from 5.6% 
to 5.1%. 
Discussion 
Interpretation of results. Representing one of the primary outcome measures for this 
project, VTE incidence was closely monitored throughout the implementation period. The 
calculated VTE incidence rate for this project was a 0.5% decrease, which was less than the 
outcome goal set at 1%. The total number of renal transplants was far less than the estimated 
figures, contributing to a smaller decrease in incidence rate. The correlational value of the 
decrease in incidence rate must be interpreted cautiously. Without a full retrospective chart 
review examining the variables contributing to the decrease, a definitive causal connection 
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between the effect of this project and the incidence rate cannot be assumed. Yet, a 0.5% decrease 
in the overall VTE incidence rate saved QMC roughly $5,770, and for every VTE readmission 
averted, approximately $8,486 (Dasta et al., 2014). 
Implications. One key implication following the implementation of this project was 
raising awareness. Awareness came in the form of not only VTEs and risk screening, but also 
EBP. While the physicians may not have considered VTEs a major problem, merely raising 
awareness of their likelihood may have subconsciously made an impact. Additionally, 
completing this EBP project and raising the awareness of the advantages of striving for up-to-
date standards of care may allow for future EBP projects.  
Limitations. Inherent with the nature of quality improvement projects, the precise 
controlling of variables, although ideal in experimental designs, was not the focus for this 
investigation. This project was conducted in a fluid environment. Conditions and variables were 
not constant. The patients were not the same, nor were the transplant physicians or their 
respective treatments. The metric for the outcomes was based on the incidence of VTE. This 
incidence was verified through findings in the medical record, notifications from other 
institutions, or by patient report. Given the time and resource constraints, there were no 
established interrater reliability or validity criteria for data collection. The data gathered was 
completed as a retrospective chart review.  
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CHAPTER 2. PROBLEM 
Introduction 
Thromboembolism is a common post-operative renal transplant complication. Studies 
have indicated this incidence can range from 7.9% to 9.1% (Poli et al., 2006; Verhave et al., 
2014). Honolulu, Hawai`i’s transplant center at The Queen’s Medical Center (QMC) reported 
this complication at 5.6%. The purpose of this evidenced-based practice (EBP) project was to 
implement and evaluate a program that decreased the incidence of venous thromboembolism 
(VTE) in adult QMCTC patients following renal transplant surgery. This chapter will describe 
the conceptual framework used to organize the project, illustrate the literature search, critique, 
and synthesis process, and conclude with a recommendation for EBP change.   
Conceptual Framework 
Implementing change within a large organization required a systems-based approach. 
Titler et al.’s (2001) Iowa Model (see Figure 1) utilizes an algorithmic flowchart approach, 
which tracks project implementation and employs feedback loops. The first step of the model is 
the identification of triggers. After the literature search, critique, and synthesis, a decision must 
be made to assess the sufficiency of the evidence to develop a practice change. If a sufficient 
evidence base has been demonstrated, the practice change is then piloted, implemented, 
evaluated, and disseminated (Schaffer, Sandau, & Diedrick, 2012).  
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Figure 1. The Iowa Model for Evidence-Based Practice. 
Note. From Titler et al. (2001) 
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Step 1: Identifying Triggers 
The Iowa Model recommended the identification of triggers, which may be problem-
focused or knowledge-focused. These triggers were designed to be the catalysts which stimulate 
critical thinking and inquiry into the development of possible EBP changes (Titler et al., 2001). 
Since 2014, The Queen’s Medical Center Transplant Center (QMCTC) conducted 124 renal 
transplant surgeries. Seven cases of VTE were reported within six months after surgery—a 5.6% 
incidence. This was the trigger for this EBP project. While the incidence rate was below the 
literature rate, four reported VTEs within a year prompted the need for this project.  
Step 2: Organizational Priority 
VTEs are life-threatening. They affect nearly 900,000 people annually in the United 
States and kill roughly 300,000. They require longer hospital stays and/or hospital readmission. 
Costs resulting from VTEs have been estimated at $4.9 to $7.5 billion for deep vein thrombosis 
(DVT) and $8.5 to $19.8 billion for pulmonary embolism (PE) annually. Mean daily costs for 
DVT and PE patients are $1,594 and $1,735, respectively, per patient (Dasta et al., 2014).  
Currently, there are no universally accepted VTE prophylaxis guidelines for renal 
transplant patients. During an investigation into the causes of the VTEs, a survey of QMCTC 
surgeons revealed varying VTE prophylaxis treatment plans based on individual surgeon 
experience and preference. Some favored only early ambulation and intermittent pneumatic 
compression (IPC), while others opted for pharmacologic interventions. For those who did not 
elect to prescribe antithrombotic pharmacologic therapy, concerns about hemorrhagic 
complications or a lack of support in the literature were noted.  
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Step 3: Team Formation 
 An interdisciplinary team of QMCTC staff was assembled to participate in this project 
(see Table B1 in Appendix B).  
Step 4: Literature Critique and Synthesis 
 Although there was substantial literature for general surgical VTE prophylaxis, studies 
focused on renal transplant VTE were minimal. As such, search parameters were broadened to 
incorporate the different aspects of the project. The search was split up into several subtopics: 
VTE risk factors, VTE risk assessment, and VTE prophylaxis. 
 An electronic search was completed utilizing PubMed, CINAHL, Google Scholar, 
National Guideline Clearinghouse, and the Cochrane Library. Keywords and medical subject 
heading terms included permutations of: “kidney OR renal transplant*”, “VTE”, “venous 
thrombo*”, “DVT”, “deep vein thrombosis”, “venous thromboembolism/prevention and 
control”, “venous thrombosis/prevention and control”, “deep vein thrombosis/prevention and 
control”, “risk OR assess*”, “risk”, “risk manage*”, “risk assess*”, “risk factors”, and “kidney 
OR renal insufficiency”.  
Articles were limited to publication within the last 20 years, English language, adult, and 
human subject results. No limits were placed on study design. Additional sources were identified 
using article reference lists.  
Eighty-seven articles published between 1997 and 2016 were identified. Forty-four 
articles were omitted based on relevance to this project. Studies focusing on renal graft 
thrombosis and renal graft survival were also excluded. The remaining 43 were examined. In 
addition, the following guidelines and recommendations for VTE and DVT prophylaxis were 
reviewed: American College of Chest Physicians, Institute for Clinical Systems Improvement, 
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National Clinical Guideline Centre for Acute and Chronic Conditions, and American College of 
Physicians. 
Evaluating the literature evidence. Mosby’s Level of Evidence was used to grade the 
evidence and internal validity into one of eight levels (see Figure 2) (Melnyk & Fineout-
Overholt, 2005). The grading results are shown in Figure 3. The “Other” level of literature 
included clinical practice guidelines (CPGs), reviews of CPGs, and literature reviews.  
 
Figure 2. Mosby’s Level of Evidence. 
Note. Adapted from Melnyk & Fineout-Overholt (2005). 
The CPGs were critiqued using the Appraisal of Guidelines for Research & Evaluation 
(AGREE) II instrument for the evaluation of CPGs (Brouwers et al., 2010). The AGREE II 
instrument uses a one to seven Likert ranking scale for 23 criteria in six domains: 1) Scope and 
purpose, 2) Stakeholder involvement, 3) Rigour of development, 4) Clarity of presentation, 5) 
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applicability, and 6) Editorial independence. For comparison and review purposes, the CPG 
scores were calculated out of a possible 161 points. The results of these scores as a percentage 
are shown in Table 1.  
 
Figure 3. Number of Articles Reviewed and Mosby’s Level of Evidence Rating. 
Note. Lit Rev = literature review; CPG = clinical practice guideline 
Table 1  
Agree II Clinical Practice Guideline Scores 
Reference Score (%) 
Gould et al. (2012). 89 
Jobin et al. (2012). 84 
National Clinical Guideline Centre for Acute and Chronic Conditions (2015). 86 
Qaseem et al. (2011). 73 
Note. Scores were calculated based on a total appraisal score divided by total possible score 161, 
rounded to the nearest whole number percentage. 
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Findings from the Literature Review 
VTE Risk Factors. It was important to delineate between normal VTE risk factors and 
VTE risk factors in the renal transplant population. Wattanakit and Cushman (2009) examined 
the association between chronic kidney disease (CKD) and VTE. The researchers proposed 
hypercoagulation mechanisms in CKD, which included the activation of procoagulation factors, 
decreased endogenous anticoagulants, enhanced platelet activation and aggregation, and 
decreased activity of the fibrinolytic system. 
Abbott, Cruess, Agodoa, Sawyers, and Tveit (2004) examined 28,924 patients receiving 
kidney transplants and found VTE was significantly more common in those with a low estimated 
glomerular filtration rate (eGFR) following surgery. In addition, other identified risk factors 
included hyperhomocysteinemia, frequent or prolonged hospitalization, sepsis, peritoneal 
dialysis over hemodialysis (HD), polycystic kidney disease (PCKD), and systemic lupus 
erythematosus (SLE).  
Similarly, Folsom et al. (2010) reviewed 10,700 cases and compared the incidence of 
VTE with eGFR. Normal kidney function had a 1.0 hazard ratio with normal eGFR, 1.40 with 
mildly impaired kidney function, and 1.94 with Stage 3 to 4 CKD.  
In a population of 95,154 patients, Mahmoodi et al. (2012) found, compared to an eGFR 
of 100 ml/min with a hazard ratio of 1.0, eGFRs of 75, 60, 45, and 30 ml/min were associated 
with VTE hazard ratios of 1.29, 1.31, 1.82, and 1.95, respectively.  
Yagmur, Frank, Neulen, Floege, and Mühlfeld (2015) studied the prevalence of platelet 
hyperaggregation in patients with CKD—specifically comparing patients on HD and renal 
transplant recipients (RTRs) with healthy control patients. Sixty-seven percent of HD patients 
and 82% of RTRs exhibited platelet hyperaggregation.  
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In addition to CKD, other proposed mechanisms predisposing RTRs to VTE included 
hematologic and genetic risk factors. Irish and Green (1997) examined 38 RTRs and found 
increased prothrombin F1+2, d-dimer, and fibrinogen contributed to a hypercoagulable state.  
Parajuli, Lockridge, Langewisch, Norman, and Kujovich (2016) reviewed the literature 
surrounding thrombosis following renal transplant. Inherited risk factors such as factor V Leiden 
mutation, prothrombin 20210G>A mutation, antithrombin deficiency, protein C or S deficiency, 
mutation in tissue plasminogen activator inhibitor-1 promoter, mutation of 
methylenetetrahydrofolate reductase, and increased lipoprotein all contributed to 
hypercoagulability. Acquired risk factors included antiphospholipid syndrome, 
hyperhomocysteinemia, cryoglobulins, cryofibrinogenemia, and acquired deficiencies of proteins 
C, S, and antithrombin. Disease states also contributory to hypercoagulability included 
disseminated intravascular coagulation, liver disease, nephrotic syndrome, and malignancy.  
In describing general risk factors for VTE, Gangireddy et al. (2007) studied 118,258 
surgical patients in the Veterans Health Administration system. Pre-operative risk factors 
associated with VTE included old age, male gender, corticosteroid use, chronic obstructive 
pulmonary disease, recent weight loss, disseminated cancer, low albumin, and low hematocrit. 
Post-operative risk factors included urinary tract infection, acute renal insufficiency, post-
operative transfusion, myocardial infarction, and pneumonia.  
Conversely, protective factors for symptomatic VTE included HD, diabetes, and higher 
pre-operative albumin levels. Humar et al. (1998) examined 1,833 RTRs and identified risk 
factors related to older age, diabetes mellitus, previous DVT, length of hospital stays, history of 
congestive heart failure, and increased body mass index. Proposed VTE etiologies included 
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pelvic dissection, venous anastomosis with clamping of the external iliac vein, decreased venous 
emptying secondary to position of the kidney, hematoma or lymphocele, and diabetes.  
With respect to the timing and risk factors associated with VTE in RTRs, Todeschini et 
al. (2013) found DVT was more frequent five to eight months following transplant. Additional 
risk factors included cyclosporine or double therapy with cyclosporine and mammalian target of 
rapamycin inhibitor, PCKD, SLE, and nephrotic syndrome.  
Verhave et al. (2014) also examined VTE risk following renal transplant surgery and 
found the incidence of VTE at one, five, and ten years was 3%, 5.8%, and 8.4%, respectively. 
The risk of VTE was eightfold in RTRs compared to the general population. Aspirin, eGFR, and 
proteinuria were not associated with thrombotic events. Risk factors included hospitalization, 
anemia, and use of sirolimus. Identified protective factors included the use of renin angiotensin 
aldosterone system (RAAS) inhibitors.  
Zanazzi et al. (2005) evaluated the risk factors in RTRs for developing VTE after a first 
episode of recurrence. In 484 RTRs, 7% of the patients developed VTE and 50% developed a 
recurrence of VTE at a median time of 18 months.  
In evaluating RTRs in Italy, Moscarelli et al. (2011) found thrombotic events occurred at 
a median of 17 months following surgery with 24% occurring during the first three months, 
15.6% three to six months following, 9.4% six to twelve months following, 13.5% one to four 
years following, and 37.5% four years or more following surgery. Other risk factors included 
long-term steroid use, hyperhomocysteinemia, cytomegalovirus (CMV) infection, cancer, male 
gender, older age, type 2 diabetes, obesity, PCKD, lymphocele, and peritoneal dialysis prior to 
transplant.  
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Given Hawai`i’s large Asian population, several studies noted a low prevalence of VTE 
in Asian patients. Yeo et al. (2015) found the incidence of VTE in Asian general surgery patients 
to be less than one percent. In comparing risk factors, the researchers found advanced stage 
cancer was the only independent risk factor. Other risk factors included age greater than 60, 
previous history of VTE, cardiovascular disease, immobilization greater than three days, post-
operative complications, and having more than two comorbidities.  
Similarly, Jun et al. (2014) evaluated the incidence of VTE in Korean RTRs and found a 
low prevalence. The researchers suggested the lack of factor V Leiden or prothrombin gene 
20210A mutations, more prevalent in Caucasian populations, may be related. 
VTE Risk Assessment. The literature described several VTE risk assessment tools. Most 
prominent were the Caprini, Padua, Kucher, and Rogers risk assessment models (RAMs). 
Caprini (2011) compared the relative strengths of the Kucher and the Anderson and Spencer 
RAMs. Caprini recommended VTE risk assessment be done as early and as soon as possible with 
a multidisciplinary team. Also emphasized was employing comprehensive and personalized VTE 
prophylaxis plans encompassing inpatient and post-discharge treatment. 
Among the VTE RAMs, the Caprini model was the most widely used and validated in the 
literature. Liu, Liu, Chen, Wu, and Lu (2016) sought to compare the validity of the Caprini and 
Padua RAMs. The Padua RAM had a lower sensitivity, but higher specificity compared to the 
Caprini RAM. The Caprini RAM tended to place many of the patients into high to super high 
risk categories, without developing VTE. 
Bilgi et al. (2016) found the Caprini RAM to be an economical, practical, and effective 
tool to stratify general surgical patients for perioperative VTE risk.  
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Lobastov et al. (2016) found a significant correlation between Caprini scores and the 
incidence of postoperative VTE in high-risk surgical patients. These results were also 
corroborated by other studies finding linear correlations between Caprini score and VTE 
incidence (Grant et al., 2016; Obi et al., 2015; Zhou et al., 2014). 
The role of electronic medical records (EMRs) and VTE risk assessment has also been 
explored in the literature. Cassidy, Rosenkranz, and McAneny (2014) reviewed an EMR-
integrated system requiring a Caprini VTE risk score for every surgical patient. Once a score has 
been inputted, the EMR generated a list of recommended prophylaxis regimens and durations. 
Surgeons could opt out of the recommended list, but were then mandated to indicate rationale.  
Kucher et al. (2005) evaluated the use of a computer-alert program designed to encourage 
VTE prophylaxis. The researchers found a computer-alert reminder system reduced the risk of 
VTE by 41%.  
In a review of an EMR assessment system, Galanter et al. (2010) evaluated a commercial 
EMR and clinical decision-support system (CDS). The researchers found a mandatory 
assessment for physicians to document VTE risk improved the rates of pharmacologic 
prophylaxis prescription and reduced the risk of VTE.  
In another review, Pannucci et al. (2014) compared physicians’ ability to accurately 
determine VTE risk compared to a computer-generated Caprini RAM program. Results showed 
physicians underestimated VTE risk by as much as six points compared to computer automation. 
Under-risk stratification by as much as two points was also significantly associated with VTE.  
Cassidy, Macht, Rosenkranz, Caprini and McAneny (2016) evaluated VTE failures 
associated with their EMR-generated thromboembolism prophylaxis protocol. While the EMR 
risk stratification tool dramatically reduced the likelihood of VTE, the researchers analyzed the 
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VTE cases for causes of failure. The VTE events may have been related to prophylaxis 
inadequacies rather than improper risk stratification or missed medications.  
VTE Prophylaxis. As there are no standardized prophylactic CPGs for renal transplant 
surgeries, much of the literature recommended individualizing therapy on a case-by-case basis. 
Gould and associates’ (2012) American College of Chest Physicians CPG established a set of 
prophylaxis recommendations for general surgery patients based on risk category and either 
Rogers or Caprini score (see Table 2).  
Table 2 
Recommended Prophylaxis Regimens Based on Caprini Score and Risk Stratification 
Caprini 
Score 
Risk Category Recommended Prophylaxis 
0 Lowest 
No specific pharmacologic or mechanical 
prophylaxis other than early ambulation 
1-2 Very Low 
Mechanical prophylaxis, 
preferably with IPC 
3-4 
Moderate, 
Low Bleed Complication Risk 
LWMH. LDUH, or mechanical 
prophylaxis, preferably with IPC 
3-4 
Moderate, 
High Bleed Complication Risk 
Mechanical prophylaxis, 
preferably with IPC 
>5 
High, 
Low Bleed Complication Risk 
LMWH or LDUH for 4 weeks with 
mechanical prophylaxis with elastic 
stockings or IPC 
>5 
High, 
High Bleed Complication Risk 
Mechanical prophylaxis, 
preferably with IPC 
>5 
High, Low Bleed Risk Complication, 
LMWH and LDUH contraindicated 
Low-dose aspirin, fondaparinux, or 
mechanical prophylaxis, 
preferably with IPC 
Note. From Gould et al. (2012). IPC = intermittent pneumatic compression; LMWH = low-
molecular-weight heparin; LDUH = low-dose unfractionated heparin 
 
As part of an EMR program, Cassidy et al. (2014) developed a simplified recommended 
VTE prophylaxis regimen based on the Caprini RAM with stratification for higher Caprini 
scores and recommended chemoprophylaxis duration (see Table 3).  
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Table 3 
Recommended Prophylaxis Regimens Based on Caprini Score and Risk Stratification 
Caprini 
Score 
Risk 
Category 
Recommended Prophylaxis Recommended Duration of 
Chemoprophylaxis 
0 Lowest 
Early frequent ambulation only OR 
at discretion of surgical team: 
Compression boots OR 
Low-dose heparin OR 
Low molecular weight heparin 
During hospitalization 
1-2 Low 
Compression boots OR 
Low-dose heparin OR 
Low molecular weight heparin 
(Choose one item) 
During hospitalization 
3-4 Moderate 
Compression boots AND 
Low-dose heparin OR 
Low molecular weight heparin 
(Choose one medication) 
During hospitalization 
5-8 High 
Compression boots AND 
Low-dose heparin OR 
Low molecular weight heparin 
(Choose one medication) 
7-10 days total 
>9 
Highest 
 
Compression boots AND 
Low-dose heparin OR 
Low molecular weight heparin 
(Choose one medication) 
30 days total 
Note. From Cassidy et al. (2014). 
Eng et al. (2011) examined the bleeding risks associated with perioperative 
anticoagulation or antiplatelet therapy. Preoperative aspirin therapy did not increase transfusion 
incidence. However, it tripled the risk of reoperation, whereas postoperative aspirin therapy 
doubled the risk. Post-operative heparin administration increased the risk of reoperation by 21-
fold. 
Similarly, Bakkaloglu et al. (2012) evaluated the necessity for heparinization following 
renal transplantation. In the early postoperative period, heparin did not significantly increase 
positive outcomes. Instead, early mobilization within 12 to 24 hours with anti-embolic 
compression socks was recommended.  
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As lymphoceles have been identified as a risk factor VTE following renal transplant 
surgery, Derweesh et al. (2008) sought to investigate the effect of placing prophylactic drains 
during transplantation. Intraoperative Jackson-Pratt (JP) drain placement in the extraperitoneal 
space dramatically reduced the incidence of VTE.  
Jun et al. (2014) also compared mechanical prophylaxis interventions in addition to the 
routine use of an intraoperative JP drain. Patients treated with IPC devices were less likely to 
develop VTE compared to those treated with graduated elastic stockings.  
Moscarelli et al. (2011) studied the effect of RAAS blockade and vitamin D medications 
as VTE prophylaxis interventions. Daily calcitriol, angiotensin-converting-enzyme inhibitor, and 
angiotensin II receptor blocker administration significantly decreased the risk of new VTE by as 
much as 60%.  
Weaknesses, Gaps, Limitations  
Although there was a sizeable amount of literature surrounding general VTE concepts, 
articles specifically related to VTE following renal transplant was limited. While the 
phenomenon has been noted in the literature, higher-level, large sample size studies have not 
been conducted. Many of the RTR-specific risk factors were based on Level IV retrospective 
cohort studies. Associations made in these articles were interpreted carefully as the may not have 
indicated causation.  
Articles comparing VTE RAMs were also generally limited to the Caprini RAM and 
articles validating the use of the Caprini RAM. Standalone articles assessing the validity of other 
VTE RAMs were uncommon.  
Another limitation was the applicability to the patient population at QMCTC. Six of the 
seven RTR VTE patients at QMCTC were Asian or part-Asian. Conversely, most the patient 
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populations in the studies included a predominantly Caucasian population. While a few of the 
studies were focused on the Asian population, higher level studies were unavailable.  
Innovation/Objectives 
The four CPGs provided a baseline for general care related to VTE. While not transplant- 
or renal transplant-specific, the CPGs recommended starting with some measure of assessment 
for VTE risk and risk of bleeding with appropriate prophylaxis intervention (Gould et al., 2012; 
Jobin et al., 2012; NCGCACC, 2015; Qaseem et al., 2011). Although not explicitly endorsing a 
specific RAM, Gould et al. (2012) listed the Rogers and Caprini RAM scores as a measure for 
appropriate prophylaxis interventions. Jobin et al. (2012) specifically recommended use of the 
Caprini RAM and outlined several interventions based on those scores. In the literature, the 
Caprini RAM was also the most widely used and validated. Studies evaluating the validity of the 
scores and value for predicting VTE events have received much support (Bilgi et al., 2016; Grant 
et al., 2016; Lobastov et al., 2016; Obi et al., 2015; Zhou et al., 2014). Mentions of other VTE 
RAMs were limited and generally cited in comparison with the Caprini RAM. One major 
drawback for the Caprini RAM was the high sensitivity and low specificity in predicting VTE 
(Liu, Liu, Chen, Wu, and Lu, 2016).  
Based on its practicality and effectiveness, the project team decided to utilize the Caprini 
RAM. However, as many of the risk factors were already contraindications to transplant surgery 
or were applicable to all patients, a modified version of the RAM was required. Additional risk 
factors identified in the literature included decreased eGFR, inherited hypercoagulable factors, 
CMV infection, and peritoneal dialysis prior to transplant (Abbott, Cruess, Agodoa, Sawyers, 
and Tveit, 2004; Folsom et al., 2010; Gangireddy et al., 2007; Mahmoodi et al., 2012; Moscarelli 
et al., 2011; Parajuli, Lockridge, Langewisch, Norman, and Kujovich, 2016; Zanazzi et al., 
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2005). While Parajuli et al. (2016) advocated for the pre-transplant screening of all patients for 
genetic or hypercoagulable risk factors, the prohibitive costs and the likelihood of incidence in 
the patient population did not justify universal screening (Jun et al., 2014; Yeo et al., 2015). 
The objective for this project was to evaluate the effect of the VTE risk assessment 
program on VTE incidence in the QMCTC adult renal transplant population over a five-month 
period. 
Summary 
Chapter 2 covered the conceptual framework used to organize the project, the literature 
search, critique, and synthesis process, and recommended practice change based on the evidence. 
The Iowa Model was used as the framework to guide this project. Steps 1 through 4 were 
covered. These steps provided an overview of the identification of triggers, determination of 
organization priority, team formation, and the search, critique, and synthesis of the evidence. The 
triggers for this project were identified as the life-threatening and costly VTEs following renal 
transplant surgeries. To explore this subject, the literature was searched using a variety of 
databases and strategies. When searching the literature, the project was separated into three 
subtopics: VTE risk factors, VTE risk assessment, and VTE prophylaxis. Following the literature 
synthesis of four CPGs and 42 articles, the Caprini RAM appeared to be most widely used and 
validated VTE RAM. A modified version of the Caprini RAM was adapted to QMCTC’s 
specifications. Redundant or not applicable risk factors were removed, while several other risk 
factors from the literature were added. Other novel VTE prophylaxis interventions were 
reviewed, but ultimately not considered due to the lack of high level, large sample size studies. 
The full details of the EBP implementation will be covered in the following chapter.    
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CHAPTER 3. METHODS 
Introduction 
A practice change at The Queen’s Medical Center Transplant Center (QMCTC) required 
a carefully structured approach to ensure implementation. Following the literature synthesis and 
critique, the Iowa Model of evidence-based practice (EBP) shifted to a pilot of the practice 
change. The implementation of this pilot included the following steps: (a) selection of outcomes 
to be achieved; (b) collection of baseline data; (c) creation of EBP guidelines; (d) 
implementation of the guidelines in a pilot trial; (e) evaluation and of the pilot trial and 
outcomes; and (f) modification of the practice guidelines based on the results of the pilot study 
(Titler et al., 2001). This chapter will describe these steps in addition to a description of the 
design, implementation, and analysis.  
PICO statement. To clarify the aims and objectives, the following problem, 
intervention, comparison, and outcome (PICO) statement, clinical question, and objective were 
developed.  
Problem/Population (P): Venous thromboembolism (VTE) in adult renal transplant 
patients. 
Intervention (I): VTE risk assessment in patients prior to renal transplant surgery. 
Comparison (C): Current practice. 
Outcome (O): VTE risk assessment for all patients prior to transplant and an overall 
decrease in the incidence of VTE. 
Clinical question. Will the implementation of an evidence-based VTE risk assessment 
program decrease the incidence of VTE by one percent in the QMCTC adult renal transplant 
population over a five-month period?   
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Objective. The objective for this project was to evaluate the effect of the VTE risk 
assessment program on VTE incidence in the QMCTC adult renal transplant population over a 
five-month period.  
Implementation Plan  
Overview. This section will cover the EBP implementation plan, including a summary of 
EBP, sampling plan, and stakeholder engagement plan. 
Evidence-based practice. EBP is the conscientious and judicious use of the evidence as 
guided by the literature (Titler et al., 2001). Utilizing Titler et al.’s (2001) Iowa Model, Steps 1 
and 2 were the identification of triggers and organizational priority for the project. They were 
identified as the life-threatening and costly VTEs following renal transplant surgeries. The team 
formation of Step 3 was also completed. The literature search of Step 4 was then conducted to 
determine the sufficiency of a research base to support a practice change.  
Practice change. At a QMCTC multi-disciplinary conference, a discussion was held on 
the feasibility and practicality of proposed practice changes from the literature. VTE risk factors, 
risk assessment models, and prophylaxis options were considered.  
A modified version of the Caprini RAM was selected and adapted to QMCTC’s 
specifications (see Appendix A). Redundant or not applicable risk factors were removed. Risk 
factors identified in the literature were added. The modified VTE risk assessment tool was 
administered to renal transplant patients prior to surgery. The results from the assessment was 
then forwarded to the transplant physician team.  
Characteristics of the innovation. 
Relative advantage. Rogers (2003) described the relative advantage of an innovation as 
the degree to which it is better than the idea it supersedes. In the pilot phase this project, the 
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feasibility of designing and implementing a VTE risk assessment program was the initial 
investment. As reimbursements for preventing readmissions are vital to the current economic 
model of health care, it was in the organization’s best interests to prevent this occurrence. While 
the adoption required an initial investment, the cost/benefit analysis should have steadily become 
more favorable as more cases of VTE were prevented.  
Compatibility. The compatibility is the degree to which an innovation is perceived as 
consistent with existing values, experiences, and needs of adopters (Rogers, 2003). This project 
furthered QMCTC’s mission to extend and enhance the quality of life through the organization’s 
commitment to excellence (Queen’s Transplant Center, 2014a). 
Complexity. The complexity is the perceived difficulty of an innovation’s understanding 
and use (Rogers, 2003). In designing this project, one of the main priorities was to ensure 
transparency in both adoption and purpose.  
Trialability. The trialability is the degree to which an innovation can be piloted on an 
experimental basis (Rogers, 2003). For this project, the risk assessment tool was administered by 
the team. The success of the project in achieving the expected outcomes may have influenced the 
permanent adoption of the VTE risk assessment program.  
Observability. The observability is the degree to which an innovation is visible to others 
(Rogers, 2003). This project was a preventive innovation—an investment to reduce the 
probability of a future adverse event. These types of innovations are challenging to demonstrate 
to potential adopters. The purported advantages are intangible or may not even occur at all, 
making the immediacy of the incentives for adoption difficult to visualize. Additional 
stakeholder engagement and education must be completed to compensate.  
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Timeline. Following the literature search and synthesis as outlined in Chapter 2, the Iowa 
Model shifted into Step 5 – Pilot the Practice Change (Titler et al., 2001). This step included the 
selection of outcomes to be achieved, the collection of baseline data, the designing of EBP 
guidelines, the pilot implementation, the evaluation of the process and outcomes, and the 
modification of the practice guidelines. As seen in Figure 4, the proposed timeline for this 
project started in May 2017 and culminated in May 2018. Step 5 was completed by the end of 
July 2017. Subsequently, Step 6, or the full practice change implementation, began in August 
2017. The implementation lasted for four months and concluded in November 2017. Step 7, or 
the evaluation of the outcomes of Step 6, took place throughout Spring 2018 and culminated with 
the final project defense in April 2018. In addition, stakeholder engagement was concurrently 
completed, as outlined in the next section. 
Sampling plan.  
Social systems. The Queen’s Medical Center (QMC) is Hawai`i’s largest private, non-
profit acute care facility (QMC, 2017). This EBP Doctor of Nursing Practice (DNP) project was 
conducted at QMCTC—the only organ transplant center in Hawai`i and the Pacific Rim 
(Queen’s Transplant Center, 2014b). The transplant center provides five transplant program 
including liver, adult kidney, pediatric kidney, pancreas, and living kidney transplant programs 
(Queen’s Transplant Center, 2014c).  
Sample.  
Population and sample. The target population was the renal transplant patients 
undergoing the assessment. The intended users for this innovation were ultimately the transplant 
physicians. An informal, pre-implementation poll of the physicians showed skepticism and 
disinterest in adopting the innovation. Thus, the targeted users shifted to the nursing staff. The 
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results from each pre-transplant risk assessment was forwarded to the transplant physicians prior 
to surgery.  
 
Figure 4. Proposed Project Timeline.  
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Due to the nature of VTE development in RTRs, timing was a critical factor. At QMCTC, 
the average length of time for the development of VTE for the eight VTE patients occurred on 
post-operation day 54.75, with a range of 15 to 112 days. QMCTC is most concerned with VTEs 
developing within six months following transplant.  
Inclusion/exclusion criteria. Patients included in this project were all QMCTC RTRs age 
18 years or older undergoing renal transplant surgery during the implementation period.    
 Application of users of the innovation. Adapted from Rogers (2003), preliminary role 
designations were made to stratify team members and stakeholders (see Table 4). Engaging these 
stakeholders is covered in the stakeholder engagement plan.  
Change agents. 
The project leader facilitates the project and establishes timelines, delegates work 
assignments, and oversees the overall process.  
The opinion leader is both respected and influential among peers and is technically well-
versed on the content material.  
Change champions are informal leaders and have positive working relationships with 
their peers. They are committed to providing quality care for their patients.  
Users are consumers of the innovation and can troubleshoot and report any challenges in 
the day-to-day usage (Rogers, 2003).  
Adopter categories. As Rogers (2003) explained, discerning adopter categories is 
important in determining innovativeness, or the timing and openness to which an innovation is 
adopted. This innovativeness curve can be separated into five standard deviations: innovators, 
early adopters, early majority, late majority, and laggards.  
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The utility of differentiating between categories determines the strategies to influence the 
buy-in from those potential stakeholders. For example, the laggards, or the transplant physicians, 
may have used the intervention’s results to better inform their practice. However, this group was 
skeptical and resistant to the applicability of the practice change to QMCTC. The challenging 
aspect in garnering their buy-in was the persuasion to adopt the innovation. Strategies for gaining 
their support needed to be tailored individually. 
Table 4 
Adopters, Role Designations, and Adopter Categories as Adapted from Rogers (2003) 
Adopters/Roles Adopter Categories 
DNP Student Project leader, innovator 
QMCTC Manager Opinion leader, early adopter 
Transplant APRN Change champion, early majority 
Transplant Care Coordinator Change agent, early majority 
Transplant Pharmacist Change champion, early majority 
Transplant Staff Users, late majority 
Transplant Physicians Users, laggards 
 
Stakeholder engagement plan. As the Centers for Disease Control and Prevention 
(CDC) (2005) noted, stakeholders are key entities within an organization and are invested in the 
program and its results. Depending on how they are engaged, stakeholders can be supportive, 
through improving credibility, implementation, advocacy, or authorization, or detrimental, 
through resistance, opposition, or criticism. Stakeholders are also tasked with ensuring the 
CDC’s four standards for evaluation—utility, feasibility, propriety, and accuracy—of the 
project’s results. These standards were selected by the CDC to aid in the decision-making 
process as part of their framework for program evaluation (CDC, 2005). 
The stakeholders for this project included a multidisciplinary team (see Table B1 of 
Appendix B). Per the Iowa Model, the specific engagement for individual stakeholders occurred 
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at different phases, depending on the support required. Tables B2 and B3 of Appendix B show an 
evaluation of stakeholder contribution to this project.  
Based on Shirey’s (2012) stakeholder analysis matrix tool, potential stakeholders were 
identified and sorted into categories based on four quadrants: manage, engage, tell, and consult 
(see Figure 5). The purpose of this stratification was to plot stakeholders based on their stake 
(horizontal axis) and influence (vertical axis) to strategically inform communication strategies 
for engagement.  
High Influence 
MANAGE 
• Administration 
ENGAGE 
• Manager 
• Physicians/surgeons 
TELL 
• Ancillary staff 
• Patients 
• Clinical pharmacist 
CONSULT 
• Clinical coordinators 
• RN staff 
Low Influence 
                Low Stake                                                                High Stake 
Figure 5. Stakeholder Mapping. 
Note. Adapted from Shirey (2012). 
 
 The manage quadrant was comprised of stakeholders with high influence, but low stake 
in the project’s outcomes. This included The Queen’s Medical Center (QMC) administrators 
concerned with a successful result. The communication aim was to appease. Engagement for 
these stakeholders took place after the practice change has been finalized and submitted for 
administration approval. 
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 The engage quadrant were those who were not only highly influential, but also had a high 
stake in the project outcome. This included the QMCTC manager, with a vested interest in the 
project and site operations, and the QMCTC physicians, skeptical about the utility of the project. 
The goal was open communication. With the respect to the Iowa Model, QMCTC manager 
engagement began from the project’s inception and continued to the conclusion.  
 The tell quadrant were those with both low influence and low stake in the project’s 
results. While they played an integral role in the daily operations of QMCTC, they did not have a 
pivotal role in the project. Communication was one-way. Engagement with the clinical 
pharmacist and ancillary staff occurred during staff training prior to the pilot implementation.  
The consult quadrant were stakeholders with low influence, but high stake in the project. 
The task was to inform and provide two-way communication. This group had direct patient 
contact and included the nursing staff and clinical coordinators. They were instrumental in the 
implementation of this project. Their engagement began during the staff training period prior to 
the pilot process and continued throughout the implementation. 
Application of communication processes. Rogers (2003) described mass media as 
having the advantages of reaching large audiences rapidly, disseminating information, and 
changing weakly-held attitudes. Interpersonal channels have the advantages of a personal, two-
way exchange of information. This allows for the possible persuasion of resistant or apathetic 
individuals. Using a concerted approach with both mass media and interpersonal channels is an 
effective strategy to reach a sizeable portion of an organization. With unlimited resources, a 
combination of emails, multimedia presentations, and visual posters would be incorporated. 
Following, the use of interpersonal channels should be used to target laggard, higher-yield 
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adopters. In-person meetings with potential laggard adopters should be held to host an exchange 
of ideas to address any concerns.  
Given time and resource constraints, a simplified and feasible communication process 
was deemed necessary. Drawing on Gagnon’s (2011) guidelines, effective knowledge 
dissemination requires several considerations. First, the content of the message should be 
straightforward, action-oriented, and tailored specifically for its intended audience. Next, the 
source or messenger should be reputable, credible, and influential with the target audience. With 
these guidelines in mind, sustainability was dependent on the buy-in from key influential 
stakeholders. Other proposed communication strategies for sustainability were informational 
training sessions and project-related email updates. 
Evaluation Plan 
Evaluation question. The evaluation question for this project was: Will the 
implementation of an evidence-based VTE risk assessment program decrease the incidence of 
VTE by one percent in the QMCTC adult renal transplant population over a five-month period?   
Integrity of the evaluation design. The evaluation plan utilized the CDC’s framework 
for program evaluation. As Milstein and Wetterhall (2000) described, the CDC framework 
encompasses six steps: 1) Engage Stakeholders; 2) Describe the Program; 3) Focus the 
Evaluation Design; 4) Gather Credible Evidence; 5) Justify Conclusions; and 6) Ensure Use and 
Share Lessons Learned. Guiding these six steps were the CDC’s four underlying standards: 
utility, feasibility, propriety, and accuracy. These standards were designed to maintain the 
evaluation plan’s accountability and ensure the validity and integrity of the results (Milstein & 
Wetterhall, 2000). 
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Utility. The results of the evaluation were directly used by several stakeholders. If the 
outcomes of the project were fulfilled, QMCTC physicians will have had the requisite evidence 
leading to a permanent practice change and paving the way for additional funding and 
authorization to implement an EMR-based risk assessment tool.      
Feasibility. The project’s implementation was relatively nonintrusive and required little 
in terms of time or resources. It was designed to be seamlessly integrated into the existing 
QMCTC workflow.  
Propriety. The project was conducted with strict observance of all patient privacy laws 
and regulations. The necessary HIPAA and privacy training were completed. Stakeholders from 
the various levels of influence and stake in the project were engaged per the stakeholder 
engagement plan.  
Accuracy. The accuracy of this project was demonstrated through adherence to project 
parameters. Interdisciplinary team members and stakeholders were engaged and invited to 
oversee the project. They ensured data collection, storage, and analysis were being completed 
through systematic, valid, and reliable means.   
Program description. The microsystem within QMCTC consisted of QMCTC staff, or 
the frontline providers of care including the transplant physicians and nurses, and the RTRs, or 
the recipients of care from the program. For the purposes of this project, the program of care was 
separated into four phases: the pre-transplant phase, the surgery phase, the inpatient post-surgery 
recovery phase, and the outpatient post-discharge phase.  
Current practice. The pre-transplant phase consisted of the pre-surgery consults. During 
this phase, the transplant physicians independently conducted their pre-surgery VTE risk 
assessment measures. Prior to the start of the project, there was no formal, standardized risk 
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assessment tool utilized by the providers. The intervention was conducted during this phase. 
After the necessary preparations, the patients underwent transplant surgery.  
New practice. The practice change was designed to take place during the pre-transplant 
phase. During this phase, the adapted Caprini VTE risk assessment was administered to all renal 
transplant patients. Subsequently, the assessments were forwarded to the transplant physicians. 
The intent was to provide a standardized and comprehensive assessment for each patient. The 
data collection monitored VTE incidence during the inpatient post-surgery recovery and 
outpatient post-discharge phases. 
 Anticipated impact on staff and patients. The intervention resulted in an added 
assessment step for staff during the pre-transplant phase. Patient medical records were reviewed 
for pertinent history. In-person interviews were conducted to verify information and gather 
details not present in the record. From the patient perspective, the intervention may have 
appeared as additional routine screening prior to surgery.  
Definitions. This project examined the effect of a VTE risk assessment screening 
program on the occurrence of VTE in QMCTC adult renal transplant patients. The evaluation 
design was impact and pre-test/post-test.  
The incidence of VTEs required a verified diagnosis in the medical record. VTEs were 
defined as encompassing both DVT and PE (Lip & Hull, 2017). DVTs were the presence of 
coagulated blood, or a thrombus, in the deep venous system most commonly in the lower 
extremities (Patel, 2016). PEs were blood thrombi that usually originate from the deep venous 
system and migrate to the lungs leading to possible hemodynamic compromise (Ouellette, 2016).  
Baseline. The collection of baseline pre-test data at T1 consisted of examining the 
number of RTR VTE incidences in the medical record prior to implementation. In addition, the 
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QMCTC physicians were surveyed on their thoughts about the topic and program (see Appendix 
C). 
Intervention. The intervention was the administration of a QMCTC-modified Caprini 
VTE risk assessment tool administered to renal transplant patients during the pre-transplant 
phase.  
Process measures. The process measure was the total number of RTRs screened. In 
addition to screening the prospective renal transplant patients, one of the transplant physicians 
proposed monitoring the change (if any) in VTE prophylaxis prescription as compared to 
previous prescription practices. This proposal was considered, however, the project team deemed 
this too research-intensive for a QIP to not only retroactively examine physicians’ past 
prescription practices, but also screen past RTRs for VTE risk factors.  
Outcome measures at T2. The outcome measure was the incidence of VTE in RTRs. The 
operational definition was incidence of VTE (DVT or PE) during the five-month implementation 
period determined by medical record diagnosis or reported hospitalizations. Following the 
completion of the intervention at T2, VTE incidence was expressed as the overall incidence of 
VTEs since 2014 (total number of VTEs divided by the total number of renal transplants 
performed) and incidence during the implementation period (total number of VTEs during the 
implementation period divided by the total number of renal transplants performed during the 
implementation period). 
The evaluation objective was set at 4.6%—one percent less than the baseline VTE 
incidence prior to implementation.  
QMCTC providers were surveyed following the conclusion of the project on their 
thoughts about the program (see Appendix D).  
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Sample. The sample population included all QMCTC RTRs age 18 years or older 
undergoing renal transplant surgery during the implementation period. All patients who fit the 
inclusion criteria were included in the sample.  
Mediating factors. As the implementation duration for this project was five months, there 
was the possibility of VTE development following the conclusion of data collection. VTEs may 
also have occurred during the implementation period, even though those patients underwent 
surgery prior to the start of this project. These factors were addressed and labeled accordingly in 
the results section. 
Data management plan. The data management plan was critical to ensure the data 
collection procedures were strictly observed, the results gained were accurate, and the analysis 
was sound. The integrity of the data management process demonstrated the credibility of the 
project’s outcomes to stakeholders. This required routine engagement of stakeholders, through 
providing a constant line of communication to foster inclusivity and transparency. 
To ensure data quality, steps were taken to maintain the veracity. The data collection 
process was streamlined to allow only a few trained team members to collect data. The training 
took place during sessions prior to implementation. Training emphasized the purpose and aims of 
the project, the use of the tools, and the information collected. Employing a select few to collect, 
input, and analyze the data was intended to reduce errors attributed to ineffective training or team 
members out of agreement. Much of the data management was completed by the project leader. 
While this may not have been ideal to ensure interrater reliability, it was necessary given the 
limited time, resources, and EBP-centered design of this project. Every effort was taken to 
safeguard the quality of the data. 
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Data sources. The source of the data was the medical record with additional information 
obtained from patient report and transplant physician survey. 
Data collection. During the screening process prior to surgery, each renal transplant 
patient’s medical record was searched for risk factors as indicated by the risk assessment tool. 
Any information not available or unclear from the medical record was asked to the patient 
directly. Each patient was assigned a number and a risk assessment file. Identifying information 
was not recorded. A summary of each patient’s VTE risk assessment was forwarded to the 
transplant physicians as they were screened.  
For the incidence of VTE, data was obtained from the medical record or by patient report 
and verification. A spreadsheet recorded each patient’s risk assessment. In the event of a reported 
VTE, the number of days post-operation to incidence was recorded. All information was stored 
on an encrypted database at QMCTC. Access was only available to authorized team members.  
 Data analysis. Following the data collection period was data analysis. Patients were 
individually analyzed based on risk assessment. In the event of VTE, the patient’s risk 
assessment score, risk factors, and pertinent treatment information was analyzed to determine a 
correlation. Descriptive statistics used to analyze the data included total count, range, and 
average. 
Stakeholders were invited to participate during the data analysis and interpretation 
process. Their input and participation increased transparency and ensured the quality of the 
results. 
Resources 
This project was not projected to require a large allocation of resources. As it was a 
quality improvement project, it was designed to be implemented with the least amount of 
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disruption to normal services as possible. The administration of the VTE risk assessment tool 
was not expected to significantly increase the time spent per patient. Although minimal, the time 
spent engaging stakeholders throughout this project should be noted.  
Financial resource allocation was negligible. Other than negligible staff time, minimal 
additional expenditures were anticipated. 
Human resources, or staff involvement, was on a voluntary basis with no mandatory 
expectations. Most of the data collection and analysis were done by the DNP student.  
Physical space or other equipment was not projected apart from a spare computer 
terminal for data collection and management. 
Dissemination Plan 
Following data collection and analysis, the next Iowa Model step was the dissemination 
of results. During this period, the results of the implementation were presented to the 
stakeholders, the organization, and the scientific community. For this project, the audience was 
primarily the QMC stakeholders with a vested interest in the results of the project—QMCTC 
staff, transplant physicians, and QMC administrators. The decision to adopt the practice change 
permanently at QMCTC was heavily influenced by the project’s ability to demonstrate 
achievement of the intended outcomes. Thus, the sustainability of this practice change was 
dependent on the results. Unsuccessful outcomes demonstrated the ineffectiveness and lack of 
applicability to QMCTC. Successful outcomes allowed for lobbying QMC administration in 
securing the necessary funding and authorizations required to make the practice change 
permanent. This project may have also served as a pilot for not only QMCTC, but also other 
QMC units affected by VTEs. 
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Human Subject Considerations 
This EBP project was designed to be a quality improvement project (QIP) with the 
primary objective to protect the rights of the human subjects involved. As this was not a 
controlled trial, there were no plans to randomize subjects to different treatments or to collect 
identifiable information. Any information gathered from retrospective chart reviews was de-
identified and encrypted. Standard evidence-based practices were implemented. Other than the 
risk associated with standard practice, there was no additional risk to the subjects. All patients 
meeting the adult renal transplant inclusion criteria were eligible for this project. Patients were 
not assigned to treatments, nor were any protected groups targeted. There was no additional risk 
to patients or staff beyond standard practice. Steps were taken to ensure there were no risks to 
patient or staff confidentiality. 
The four ethical tenets—autonomy, non-maleficence, beneficence, and justice—were 
observed to ensure the project was ethically sound.  
With respect to autonomy, both the transplant patients and providers could opt out of 
participating in the project. The patients were not mandated to provide any information via the 
risk assessment tool. Similarly, the providers were not obligated to use any of the risk assessment 
data to influence their practice.  
With non-maleficence in mind, this project was not designed to cause any additional 
harm other than usual care. The transplant providers only received VTE risk assessments. They 
were solely responsible for prescribing treatments.  
Beneficence was observed as every patient’s risk for VTE was elucidated. The patients 
may have benefited from a thorough VTE risk assessment. The providers may have benefited 
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from receiving a more complete clinical picture without expending time to conduct a detailed 
chart review.  
Justice was maintained through the relatively broad inclusion and exclusion criteria. 
Patients need only have been over the age of 18 to be included in the project.  
The DNP student completed the University of Hawai`i Collaborative Institutional 
Training Initiative (CITI) course on Human Subjects Protection. In addition, a project application 
was approved by the Queen Emma Nursing Institute (QENI)—the program charged with 
promoting nursing excellence and overseeing QIPs at QMC (QENI, n.d.). Further approval was 
also granted by QMC Office of Research and Developmental institutional review board.  
Limitations 
The precise controlling of variables, although ideal in experimental designs, was not the 
focus for this investigation. This project was conducted in a fluid environment. Conditions and 
variables were not constant. The patients were not the same, nor were the transplant physicians 
or their respective treatments. Any conclusions drawn from the results of this project were 
considered correlational.  
Due to the already small renal transplant population size, any restrictions accounting for 
distribution or representativeness would further reduce the sample size. This necessitated broad 
inclusion criteria and convenience sampling.  
The metric for the outcomes was based on the incidence of VTE. This incidence was 
through verified diagnosis findings in the medical record, notifications from other institutions, or 
by patient report. Given the time and resource constraints, there were no established interrater 
reliability or validity criteria for data collection.  
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There were several possibilities for false negative results. First, if a VTE diagnosis was 
not noted in a patient’s record during the data collection period, the incidence may have gone 
unrecorded. Next, a patient may have suffered from a VTE and sought treatment from an 
institution outside the QMC system. If the outside institution or the patients did not report this 
incidence to QMCTC, it may not have been recorded. Finally, there was also the possibility of 
the incidence of asymptomatic VTEs. Due to resource constraints, periodic post-surgery 
universal ultrasonography screening was considered, but deemed not financially feasible. 
The data gathered was completed as a retrospective chart review. The quality of the data 
was largely dependent on health care providers’ entries into the medical record. Procedurally, 
there was a variable timing of data collection as the renal transplant patients were screened.  
Summary  
The purpose of this DNP project was to decrease the incidence of VTE in the QMCTC 
adult renal transplant population following surgery. This chapter served as an overview 
describing the process to transition from the theoretical to a quality improvement practice 
change. In this chapter, the procedures for Step 5 of the Iowa Model, the piloting of the practice 
change, Step 6, the practice change implementation, and Step 7, the evaluation of project 
outcomes were described. The sampling plan was also illustrated, including the users of the 
innovation, key categories for stakeholders, the social system, and sample. Plans for stakeholder 
engagement were presented, along with the communication strategies, such as in-person 
meetings or emails to be utilized. A program evaluation plan modeled on the CDC’s framework 
was also introduced. Finally, the resources, dissemination plan, human subject considerations, 
and limitations were explicated. 
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CHAPTER 4. RESULTS 
Objective 
 The objective for this project was to evaluate the effect of the VTE risk assessment 
program on VTE incidence in the QMCTC adult renal transplant population over a five-month 
period. A standardized VTE risk assessment tool was created. The widely-validated Caprini tool 
was selected from the literature and adapted to QMCTC’s specifications. The tool was then used 
on all adult renal transplant patients. The effect of the VTE risk assessment program was 
measured through VTE incidence.  
Step 5: Practice Change Pilot 
 With the necessary resources and team members in place, the project was piloted for one 
month in August 2017. Due to the time-critical nature of transplant services, the team decided it 
would be most efficient for the DNP student to conduct all VTE risk assessment screenings. The 
narrow period between organ procurement, obtaining consent, and actual surgery left little time 
for the staff to implement this project. 
Step 6: Practice Change Implementation  
 The full practice change implementation was conducted for four months following the 
pilot period. After QMCTC received notice of possible organ availability, prospective organ 
recipient matches were notified and brought in for consent. In the succession of pre-transplant 
processing involving consent, social work, and finance, the DNP student was allowed a brief 
window to speak with patients to complete the VTE risk assessment screen. Depending on the 
amount of information gained from the medical record, the total time spent with each patient was 
on average under three minutes. Data was collected as outlined in the Data Management Plan of 
Chapter 3. Following the VTE screening, transplants were not conducted in many of the cases 
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due to unsatisfactory organ quality, unavailability of the organ, or insufficient status on the 
recipient waitlist.  
Step 7: Evaluate Outcomes 
Description of sample. Twenty-two patients were potential candidates for renal 
transplant during the implementation period. Twenty-one of those patients were above the age of 
18 and met inclusion criteria and underwent VTE risk assessment screening. Twelve of those 
patients underwent renal transplant surgery. The patient numbering scheme reflected the original 
order the patients were screened with consideration to those who did not undergo transplant. The 
data from those patients who did not undergo transplant was omitted from the results. Eleven of 
the patients were male (92%). The average age of the patient population was 49 years (range 28 
to 68 years), with four patients each in the under 40 years, 40 to 60 years, and above 60 years age 
groups. Most of the patients were Asian or part-Asian (92%), while 17% of the patients were 
Caucasian or part-Caucasian (see Figure 6).  
Level 1 Risk Factors. The most predominant Level 1 Risk Factors were age 40-59 years 
(33%) and major surgery (25%). One patient had swelling in his leg due to recent surgical 
revision of an arteriovenous graft (8.3%) (see Table E2 of Appendix E). 
Level 2 Risk Factors. Age 60 to 74 years was the only Level 2 Risk Factor (33%) (see 
Table E3 of Appendix E). 
 Level 3 Risk Factors. There were no Level 3 Risk Factors identified in the sample 
population, although one patient’s family history for DVT or PE could not be assessed as he was 
adopted (see Tables E4 and E5 of Appendix E). 
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Figure 6. Renal Transplant Recipient Self-Reported Ethnicities.  
Note. Multiracial included those of more than one ethnicity. The ethnicities for the two 
multiracial patients were Hawaiian, Filipino, and Japanese and Samoan, Portuguese, and 
Japanese.  
 Literature Risk Factors. For literature risk factors, one patient was on peritoneal 
dialysis (8.3%). Low hematocrit (less than 40% for males and less than 36% for females) was 
identified in 92% of the patient sample (range 28.8% to 39%) (see Table E6 of Appendix E). 
Trend analysis for process and outcome measures. 
 Process measures. The process measure for this project was the total number of RTRs 
screened. Twelve of the total twelve renal transplant patients meeting the inclusion criteria were 
screened prior to surgery.  
 Outcome measures. Outcomes for this project were measured by the incidence of VTE in 
the RTR population. During the five VTE checks at the end of August, September, October, 
November, and December 2017, zero incidence of VTE was noted in the RTR records. The VTE 
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incidence rate in the RTR patient sample was 0%. The overall incidence rate since 2014 
decreased from 5.6% to 5.1%. 
 Transplant physician survey. QMCTC transplant physicians were provided with surveys 
before and after the implementation period (see Appendices C and D, respectively). The 
response rate for the pre-survey was 60%, while the post-survey was 40%.  
In the pre-survey, the respondents indicated VTEs were a minor problem at QMCTC 
(100%). Each physician felt differently on the priority to assess patients for VTE risk prior to 
transplant—medium priority (33%), high priority (33%), and essential (33%). The physicians 
were also neutral (33%), somewhat comfortable (33%), and very comfortable (33%) with their 
comfort in assessing VTE risk. All the physicians indicated they considered, but did not use a 
validated VTE risk assessment tool (100%). Regarding the project, the physicians noted the 
usefulness of the project to their practice would be slightly useful (33%), somewhat useful 
(33%), and very useful (33%). When asked on who should complete VTE risk assessments, the 
physicians felt the transplant nephrologist (33%), transplant APRN (33%), and transplant patient 
care coordinator (33%). On the likelihood of continuing to use a VTE risk assessment tool, the 
physicians indicated they would be neutral (33%), likely (33%), and extremely likely (33%).  
In the post-survey, the physicians noted the information from the project was slightly 
useful (50%) and somewhat useful (50%). With regards to the effect on their prophylaxis 
decisions, the physicians indicated there was a neutral influence (100%). The physicians were 
neutral (50%) and somewhat favored (50%) the notion of continuing the project’s VTE 
screening.  
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Evolution of Project 
 Expected vs. actual outcomes. Outcomes for this project were expressed as the 
incidence of VTEs in the RTR population and additionally physician support for the project. It 
was expected the incidence of VTE would be zero following the implementation period and the 
incidence rate of VTE would decrease by one percent. It was also expected there would be 
roughly five to eight renal transplant patients per month based on numbers from previous years. 
Following the conclusion of the project, the actual number of VTEs was zero, meeting 
expectations, however, the actual decrease in VTE incidence rate decreased by only 0.5%. The 
actual patient sample was smaller than expected. Over the course of the five-month 
implementation period, there were only 12 renal transplant patients who underwent surgery. 
While there was nearly double the number of patients screened, most of those did not undergo 
surgery due to unsatisfactory organ quality or insufficient priority status on the recipient list.  
 Physician support for this project had been neutral and pessimistic since its inception. 
Their skepticism on the need from a project was evident in their pre- and post-surveys. It was 
expected the information gathered from the project would support the continued usage of the 
VTE risk assessment program created. In practice, the period between organ availability 
notification to transplant surgery was very narrow. It was understandable the physicians most 
likely were not able to check their email for VTE risk assessment reports. A limited patient pool 
coupled with correlational results did little to provide further support for this project.  
 Facilitators. The staff of QMCTC were integral to this project. Although the demanding 
nature of their work prevented them from conducting screenings, their enthusiasm and 
willingness to provide other assistance aided in the project’s completion.   
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 Barriers. The negligible budget for this project was one of the key limiting factors for 
this project. With adequate funding, staff may have been compensated to complete the VTE 
screening. Additional barriers included the lack of EMR-integrated support for the screening 
program. The DNP student also did not have full EMR access with the ability to create notes in 
the EMR to relay screening data.  
Summary 
 Chapter 4 included the Iowa Model steps 5, 6, and 7. These steps outlined the pilot of the 
practice change, the implementation of the practice change, and the evaluation of outcomes.  
 The QMCTC VTE risk assessment program screened a total of 22 patients over a five-
month implementation period. Only 12 of the 22 patients underwent renal transplant surgery. 
Among the RTRs, age 40 to 59 years and prior major surgery made up the most common Level 1 
Risk Factors. Age 60 to 74 years was the only Level 2 Risk Factor. There were no Level 3 Risk 
Factors identified. Low hematocrit was the most common literature risk factor identified.  
 Among the QMCTC physicians, VTEs were thought of as a minor problem and they 
considered, but did not currently use a validated VTE risk assessment tool. The physicians were 
also neutral on the effect of the project’s VTE screening information on their prophylaxis 
prescription practices.  
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CHAPTER 5. DISCUSSION 
Interpretation of Findings 
 VTE incidence. Representing one of the primary outcome measures for this project, VTE 
incidence was closely monitored throughout the implementation period. The calculated VTE 
incidence rate for this project was a 0.5% decrease, which was less than the outcome goal set at 
1%. This goal was arbitrarily based on the projected average number of renal transplant surgeries 
conducted per month in the past. With a decrease in the number renal transplants, there was a 
proportionate decrease in the calculated VTE incidence rate. The total number of renal 
transplants was far less than the estimated figures, contributing to a smaller decrease in incidence 
rate.  
Although there was only a 0.5% decrease in the overall VTE incidence rate, the savings 
in possible VTE aversions to QMC can be calculated. Using the figures of Dasta et al. (2014), 
with an average length of stay of 5.1 days and an average daily cost per patient of $1,664, a 0.5% 
decrease amounts to a savings of $5,770. In addition, for every VTE readmission averted, it 
saved QMC approximately $8,486.  
 As QMCTC was only concerned with VTEs that occurred in the six months following 
transplant, the sample population should have also been followed for six months. However, due 
to time constraints, the full VTE observation period post-surgery was not completed. The longest 
observation period was four months, while the shortest was one month. It was possible, 
following the conclusion of this project, VTE cases may still have developed, altering the VTE 
incidence rate. Other possibilities were unrecorded VTEs who sought treatment outside the QMC 
system or asymptomatic VTEs.  
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The correlational value of the decrease in incidence rate must be interpreted cautiously. 
Numerous factors may have contributed to this apparent decrease. Without a full retrospective 
chart review examining the variables contributing to the decrease, a definitive, causal connection 
between the effect of this project and the incidence rate cannot be assumed.  
Transplant physician survey. The other outcome measure was based on the transplant 
physician pre- and post-surveys. The low response rates for the survey may have been indicative 
of the waning interest in the project. Three out of five (60%) and two out of five (40%) 
physicians participated in the pre- and post-surveys, respectively. While the response rates may 
have been low, those who responded provided valuable insight and feedback. As indicated by all 
respondents, VTEs at QMCTC were a perceived minor problem. This may have been a result of 
the time difference between cases. There have been no recorded cases of VTE in the RTR 
population since May 2, 2016. Prior, there was only one case on March 3, 2016. There were no 
VTE cases in 2015 and four cases in 2014 in January, February, October, and December. This 
clustered nature of incidence coupled with long periods of no incidence may have contributed to 
the physicians downplaying the severity of the problem.  
However minor, the physicians still felt screening for VTEs was necessary on a medium 
to essential priority, suggesting a possible need for this project. Yet, in the post-survey, the 
physicians were indifferent to the usefulness of the information gathered and felt it had a neutral 
influence on their prescription decisions. The sustainability of the project will largely be 
dependent on the support from the physicians. If they did not use the risk assessment screen 
information, then the effort and energy expended on gathering the information was wasted.  
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Implications and Recommendations 
 Recommendations from this EBP quality project included adding the QMCTC-modified 
Caprini tool to the routine pre-transplant process. As expected, the administration of the VTE 
tool did not significantly increase patient contact time. Coupled with the estimated savings of 
$8,486 and relatively low cost to implement, QMC administrators should consider continuing 
this screening program. To expedite information entry, an EMR-based approach needs to be 
developed. Possible options include an EMR checklist in each patient’s record or logging the 
results of the VTE tool screen in a note. Utilizing the EMR should make the information more 
conveniently accessible for physicians.  
 Per physician recommendation, the VTE risk assessment screen should be completed by 
the transplant nephrologist, transplant APRN, or transplant patient care coordinator prior to 
surgery.  
 One key implication following the implementation of this project was raising awareness. 
Awareness came in the form of not only VTEs and risk screening, but also EBP. While the 
physicians may not have considered VTEs a major problem, merely raising awareness on their 
likelihood may have subconsciously made an impact. Additionally, completing this EBP project 
and raising the awareness of the advantages of striving for up-to-date standards of care may 
allow for future EBP projects.  
Although out of the scope of this quality improvement project, a retrospective analysis of 
every RTR since 2014 should be conducted. In this review, patients should be screened for VTEs 
using the QMCTC-modified Caprini tool cross-referencing risk assessments with postoperative 
VTE prophylaxis care. As suggested by one of the physicians in their post-survey, the 
prophylaxis prescription practices of the physicians should also be compared pre-project 
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implement and post-implementation to note any changes in practice to quantify a change in 
awareness.  
DNP Essentials 
 The American Association of Colleges of Nursing (AACN) (2006) developed a set of 
essentials critical for all Doctor of Nursing Programs. These essentials are the core competencies 
required for all advanced nursing roles. A summary of the AACN essentials as they aligned with 
this project is presented in Appendix F.  
Plans for Dissemination 
 The results will be disseminated via several methods including oral presentations, briefs, 
and formal written publications. These methods will report the project findings to various 
audiences including QMC stakeholders and the transplant community. The dissemination of 
information represents a critical aspect to contributing new knowledge to the existing body of 
literature. Other institutions may examine the outcomes and learn from the challenges and 
improve upon this project to ultimately provide quality, evidence-based care for patients. 
Summary  
 Chapter 5 interpreted the results generated by this EBP quality improvement project. 
Following the implementation of the VTE risk assessment program, the overall VTE incidence 
rate decreased. While not a direct causative correlation, the results may have had an indirect 
effect of raising physician awareness on VTEs and EBP. Recommendations to increase the 
sustainability of this program were discussed, including the addition of the risk screen to the 
existing pre-transplant preparation process and streamlining the information dissemination 
through EMR integration. The AACN DNP Essentials were also described as they aligned with 
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this project. This chapter closed with plans for disseminating the findings of this project for the 
benefit of the organization and transplant community.  
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Appendix A 
Modified Caprini Venous Thromboembolism Risk Assessment Tool 
Level 1 Risk factors (1 point) 
o Age 40-59 years 
o History of prior major surgery 
o Varicose veins 
o History of inflammatory bowel disease  
o Swollen legs (current) 
o Obesity (BMI >30) 
o Abnormal pulmonary function (COPD) 
o Leg plaster cast or brace 
o Blood transfusion (<1 month) 
 
Level 1 Risk factors for women (1 point)  
o Oral contraceptives or hormone replacement therapy 
o History of unexplained stillborn infant, recurrent spontaneous abortion (>3), premature 
birth with toxemia of pregnancy, or growth restricted infant 
 
Level 2 Risk factors (2 points) 
o Age 60-74 years 
o Previous malignancy 
 
Level 3 Risk factors (3 points) 
o Age 75 years or more 
o History of SVT, DVT/PE 
o Family history of DVT/PE 
o Present factor V leiden 
o Positive prothrombin 20210A 
o Elevated serum homocysteine 
o Positive lupus anticoagulant  
o Elevated anticardiolipin antibodies 
o Heparin-induced thrombocytopenia (HIT) 
o Other thrombophilia __________________ 
 
Literature Risk Factors 
o Peritoneal dialysis 
o Sedentary lifestyle 
o Low albumin (<3.5 g/dl) 
o Low hematocrit (<40% for men and <36% for women) 
o CMV infection 
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Appendix B 
Table B1  
Project Team and Stakeholder Roster 
Position Project Role 
DNP Student  Conduct chart review, collect data 
Transplant Center Manager Content expert, change champion, opinion leader 
Transplant APRN Content expert, change champion 
Transplant Patient Care Coordinator Content expert, change champion 
Transplant Pharmacist Content expert, opinion leader 
PI Coordinator Change champion 
Staff Ancillary support 
Transplant Physicians Consumer of intervention 
Administration Oversees results 
Note. DNP = doctor of nursing practice; APRN = advanced practice registered nurse; PI = 
principal investigator.  
 
Table B2 
Stakeholder Contribution Evaluation  
Position 
 
Increasing 
credibility 
Assist in 
design of 
evaluation 
plan 
Implementing 
the 
intervention 
Advocate 
for 
changes 
Fund or 
authorize 
action to 
implement 
findings 
QMCTC Manager x x  x x 
Transplant APRN x x x x  
Transplant Patient Care 
Coordinator 
x x x x  
Transplant Pharmacist x x    
Transplant Staff x  x   
Transplant Physicians x     
QMC Administrators     x 
Note. QMCTC = Queen’s Medical Center Transplant Center; APRN = advanced practice 
registered nurse; QMC = The Queen’s Medical Center. 
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Table B3 
Stakeholder Support Evaluation 
Position 
Program 
Description 
Evaluation 
Question 
Data 
Collection 
Data 
Management 
Data 
Analysis 
Dissem
-ination 
QMCTC Manager x x x x  x 
Transplant APRN x x x    
Transplant Patient 
Care Coordinator 
x x x    
Transplant Pharmacist x x     
Transplant Staff   x    
Transplant Physicians x      
QMC Administrators       
Note. QMCTC = Queen’s Medical Center Transplant Center; APRN = advanced practice 
registered nurse; QMC = The Queen’s Medical Center. 
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Appendix C 
Pre-implementation Transplant Physician Survey 
1. How much of a problem is thrombosis post-kidney transplant at The Queen’s Transplant 
Center?  
1 – Not a problem at all 
2 – Minor problem 
3 – Moderate problem  
4 – Severe problem 
 
2. How much of a priority is it to assess patients for thrombotic risk prior to kidney transplant? 
1 – Not a priority 
2 – Low priority  
3 – Medium priority  
4 – High priority  
5 – Essential  
 
3. How comfortable are you in assessing patients for thrombotic risk prior to kidney transplant? 
1 – Very uncomfortable  
2 – Somewhat uncomfortable 
3 – Neutral 
4 – Somewhat comfortable 
5 – Very comfortable  
 
5. Do you currently use a validated, standardized thrombosis risk assessment tool? 
1 – No, and not considered 
2 – No, but considered 
3 – Yes, but I use my own tool or adapted tool  
4 – Yes, I use a validated, standardized tool  
 
6. If a standardized thrombosis risk assessment tool were to be used on your patients, how useful 
would the information be to your practice? 
1 – Not at all useful 
2 – Slightly useful  
3 – Somewhat useful  
4 – Very useful  
5 – Extremely useful  
 
7. Whose responsibility should it be to complete the standardized thrombosis risk assessment 
tool?  
1 – Physician/surgeon 
2 – Nursing staff 
3 – Patients should fill it out themselves  
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8. How likely are you to continue using the standardized thrombosis risk assessment tool? 
1 – Extremely unlikely 
2 – Unlikely  
3 – Neutral  
4 – Likely  
5 – Extremely likely  
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Appendix D 
Post-implementation Transplant Physician Survey 
1. How useful was the information from the thrombosis risk assessment tool? 
1 – Not at all useful 
2 – Slightly useful  
3 – Somewhat useful  
4 – Very useful  
5 – Extremely useful  
 
2. The information from this thrombosis risk assessment tool influenced my prophylaxis 
decisions.  
1 – Strongly disagree 
2 – Disagree  
3 – Neutral  
4 – Agree  
5 – Strongly agree  
 
3. Should this thrombosis risk assessment be continued?  
1 – Strongly oppose 
2 – Somewhat oppose  
3 – Neutral  
4 – Somewhat favor  
5 – Strongly favor  
 
4. How could this thrombosis risk assessment tool be improved?  
 
 
 
 
5. Other comments and feedback.  
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Appendix E 
Table E1 
Summary of RTR Patient Demographics 
Patient Number Age (years) Sex Ethnicity 
2 28 M Filipino 
4 50 M Filipino 
5 68 M Japanese 
8 61 F Chinese 
12 65 M Filipino 
13 63 M Japanese 
14 49 M Japanese 
15 53 M Filipino 
16 49 M Hawaiian, Filipino, Japanese 
18 36 M Filipino 
21 29 M Samoan, Portuguese, Japanese 
22 37 M Caucasian 
Note. The data for the patients who did not undergo transplant surgery has been omitted. RTR = 
renal transplant recipient. 
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Table E2 
Summary of RTR QMCTC-modified Caprini Tool Level 1 Risk Factors 
Patient 
Number 
Age 
(years) 
Age  
40-59 
(years) 
History of 
Prior Major 
Surgery 
Varicose 
Veins 
History 
of IBD 
Swollen Legs 
(Current) 
Obesity 
(BMI 
>30) 
COPD 
Leg 
Plaster 
Cast or 
Brace 
Blood 
Transfusion  
(<1 month) 
2 28          
4 50 50         
5 68  Cardiac 
stent 
       
8 61          
12 65          
13 63          
14 49 49 Liver and 
kidney 
transplant 
       
15 53 53 Kidney 
transplant 
       
16 49 49         
18 36          
21 29     RLE swelling 
from recent 
AVG revision 
    
22 37     (BLE 
amputation) 
    
Note. The Level 1 Risk Factors for Women for Patient 8 were negative and have been omitted. For clarity, blank results indicate a 
negative value. RTR = renal transplant recipient; QMCTC = Queen’s Medical Center Transplant Center; IBD = inflammatory bowel 
disease; BMI = body mass index; COPD = chronic obstructive pulmonary disease; RLE = right lower extremity, AVG = arteriovenous 
graft; BLE = bilateral lower extremity 
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Table E3 
Summary of RTR QMCTC-modified Caprini Tool Level 2 Risk Factors 
Patient Number Age (years)  Age 60-74 (years) History of Cancer 
2 28    
4 50    
5 68  68  
8 61  61  
12 65  65  
13 63  63  
14 49    
15 53    
16 49    
18 36    
21 29    
22 37    
Note. For clarity, blank results indicate a negative value. RTR = renal transplant recipient; QMCTC = Queen’s Medical Center 
Transplant Center. 
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Table E4 
Summary of RTR QMCTC-modified Caprini Tool Level 3 Risk Factors 
Patient 
Number 
Age 
(years) 
Age 75+ 
(years) 
History of SVT, 
DVT, or PE 
Family History of DVT or 
PE 
Factor V 
Leiden 
Prothrombin 
20210A 
2 28    Not tested Not tested 
4 50   (Unknown - patient was 
adopted) 
Not tested Not tested 
5 68    Not tested Not tested 
8 61    Not tested Not tested 
12 65    Not tested Not tested 
13 63    Not tested Not tested 
14 49    Not tested Not tested 
15 53    Not tested Not tested 
16 49    Not tested Not tested 
18 36    Not tested Not tested 
21 29    Not tested Not tested 
22 37    Not tested Not tested 
Note. For clarity, blank results indicate a negative value. RTR = renal transplant recipient; QMCTC = Queen’s Medical Center 
Transplant Center; SVT = superficial venous thrombosis; DVT = deep vein thrombosis; PE = pulmonary embolism. 
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Table E5 
Summary of RTR QMCTC-modified Caprini Tool Level 3 Risk Factors 
Patient 
Number 
Elevated Serum 
Homocysteine 
Lupus 
Anticoagulant  
Elevated Anticardiolipin 
Antibodies 
Heparin-induced 
Thrombocytopenia 
Other 
Thrombophilia 
2 Not tested Not tested Not tested Not tested  
4 Not tested Not tested Not tested Not tested  
5 Not tested Not tested Not tested Not tested  
8 Not tested Not tested Not tested Not tested  
12 Not tested Not tested Not tested Not tested  
13 Not tested Not tested Not tested Not tested  
14 Not tested Not tested Not tested Not tested  
15 Not tested Not tested Not tested Not tested  
16 Not tested Not tested Not tested Not tested  
18 Not tested Not tested Not tested Not tested  
21 Not tested Not tested Not tested Not tested  
22 Not tested Not tested Not tested Not tested  
Note. For clarity, blank results indicate a negative value. RTR = renal transplant recipient; QMCTC = Queen’s Medical Center 
Transplant Center. 
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Table E6 
Summary of RTR QMCTC-modified Caprini Tool Literature Risk Factors 
Patient Number Peritoneal Dialysis (PD) Sedentary Lifestyle 
Low Albumin 
(<3.5 g/dL) 
Low Hematocrit 
(<40% M, <36% F) 
CMV Infection 
2  Denies  32.6%  
4  Denies  37.5%  
5  Denies  33.2%  
8  Denies    
12  Denies  31.1%  
13 On PD Denies  28.8% Not tested 
14  Denies  33.9%  
15  Denies  38.1%  
16  Denies  34.2%  
18  Denies  34.5%  
21  Denies  29.7%  
22  Denies  39% Not tested 
Note. For clarity, blank results indicate a negative value. RTR = renal transplant recipient; QMCTC = Queen’s Medical Center 
Transplant Center; CMV = cytomegalovirus. 
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Appendix F 
Table F1 
Summary of AACN Essentials and this DNP Project 
Essential Selected Description Project Demonstration 
I: Scientific Underpinnings for 
Practice 
Integrate nursing science with knowledge 
from ethics, the biophysical, psychosocial, 
analytical, and organizational sciences as 
the basis for the highest level of nursing 
practice.  
The EBP nature of this project involved the 
integration of concepts from the sciences and 
translating them into a practice change.  
II: Organizational & Systems 
Leadership for Quality 
Improvement and Economics 
Develop and evaluate care delivery 
approaches that meet current and future 
needs of patient populations based on 
scientific findings in nursing and other 
clinical sciences, as well as 
organizational, political and economic 
sciences.  
This EBP project demonstrated the design, 
implementation, and evaluation of a project based 
on the needs of the renal transplant population. 
III: Evidence-Based Practice & 
Translation Science 
Use analytic methods to critically appraise 
existing literature and other evidence to 
determine and implement the best 
evidence for practice.  
Chapter 2 describes the critical search and 
appraisal of the literature and the translation of 
those findings into the development of a practice 
change.  
IV: Information Systems & 
Technology 
Design, select, use, and evaluate programs 
that evaluate and monitor outcomes of 
care, care systems, and quality 
improvement including consumer use of 
health care information systems.  
Chapter 3 describes the development of an 
evaluation program to monitor the outcomes for 
this project. 
Note. Adapted from AACN (2006). AACN = American Association of Colleges of Nursing; DNP = Doctor of Nursing Practice; EBP 
= evidence-based practice.
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Table F2 
Summary of AACN Essentials and this DNP Project 
Essential Selected Description Project Demonstration 
V: Health Care Policy 
& Ethics 
Demonstrate leadership in the 
development and implementation of 
institutional, local, state, federal, and/or 
international health policy.  
A quality improvement program was developed through this 
project. The outcomes of the project informed the possible 
need for an institutional change in health policy.  
VI: Inter-professional 
Collaboration 
Lead interprofessional teams in the 
analysis of complex practice and 
organizational issues.  
Chapter 2 describes the formation of team of 
interdisciplinary team members tasked with the design, 
implementation, and evaluation of this project. 
VII: Prevention and 
Population Health  
Synthesize concepts, including 
psychosocial dimensions and cultural 
diversity, related to clinical prevention 
and population health in developing, 
implementing, and evaluating 
interventions to address health 
promotion/disease prevention efforts, 
improve health status/access patterns, 
and/or address gaps in care of individuals, 
aggregates, or populations.  
One of the goals of this project was to prevent and reduce 
the incidence of VTEs (clinical prevention). This project 
was a program to address this clinical issue.  
VIII: Advanced 
Nursing Practice & 
Education 
Design, implement, and evaluate 
therapeutic interventions based on nursing 
science and other sciences.  
This EBP project encapsulated the design, implementation, 
and evaluation of an intervention, as directed by the 
literature.  
Note. Adapted from AACN (2006). AACN = American Association of Colleges of Nursing; DNP = Doctor of Nursing Practice; EBP 
= evidence-based practice; VTE = venous thromboembolism.  
